Studies have shown that IL-17A can promote ESCC tumor cells to produce more chemokines CCL2, CCL20, and CXCL13, enhance B cell migration, or enhance IgG-mediated antibody and complement-mediated cytotoxicity of B cells to tumor cells to inhibit tumor development. This evidence concerns the gene IL17A and neoplasm.